The Indian pharmaceutical landscape is set for a significant shift as Novo Nordisk's patent for semaglutide expires this week. This expiration allows local drugmakers to introduce significantly cheaper generic versions of popular diabetes and weight-loss medications. Major Indian players, including Sun Pharma and Dr. Reddy's, are expected to capitalize on this opportunity to capture substantial market share. However, industry experts have raised concerns regarding regulatory oversight as the market potentially becomes overcrowded with various generic alternatives. While the move poses a challenge to Novo Nordisk's revenue exclusivity in India, the company maintains robust global demand and patent protection in other key regions. The entry of affordable generics is anticipated to increase accessibility for patients while intensifying competition within the Indian healthcare sector.
Sign up free to access this content
Create Free Account